RTP Mobile Logo
Oncology Grand Rounds Series: Part 4 — Chronic Lymphocytic Leukemia (Webinar Audio Proceedings)
Released July 2020

Proceedings from the fourth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Amy Goodrich, Dr Brad S Kahl, Ms Robin Klebig and Dr Jeff Sharman. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia (CLL).

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE (NCPD) activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with CLL.

    LEARNING OBJECTIVES

    • Apply available clinical information and research data to the therapeutic and supportive care of patients with CLL.
    • Appreciate the importance of clinical presentation, biomarker profile, coexisting medical conditions and psychosocial status in the selection of systemic therapy for newly diagnosed CLL.
    • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase inhibition with ibrutinib or acalabrutinib compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to discern how this strategy can be optimally integrated into nonresearch treatment.
    • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how this regimen can be appropriately integrated into current treatment decision-making.
    • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies employed in the management of CLL in order to support quality of life and continuation of therapy.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with CLL to optimize clinical and quality-of-life outcomes.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENTS
    Audio Program: This educational activity for 2.25 contact hours is provided by RTP during the period of August 2020 through August 2021.

    This activity is awarded 2.25 ANCC pharmacotherapeutic contact hours.

    Video Program: This educational activity for 1.5 contact hours is provided by RTP during the period of July 2020 through July 2021.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/Meetings/ONS2020/CLL/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the mp3s, review the downloadable slide sets, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCLL2020/CNE. The corresponding video program is available as an alternative at ResearchToPractice.com/ONSCLL2020/Video. Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCLL2020/Video/CNE. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONSCLL2020.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Amy Goodrich, CRNP
    Nurse Practitioner
    The Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Medicine
    Baltimore, Maryland

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc.

    Brad S Kahl, MD
    Professor of Medicine
    Washington University School of Medicine
    Director Lymphoma Program
    Siteman Cancer Center
    St Louis, Missouri

    Advisory Committee: AstraZeneca Pharmaceuticals LP; Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, BeiGene, Celgene Corporation, Genentech, a member of the Roche Group; Data and Safety Monitoring Board: Celgene Corporation.

    Robin Klebig, APRN, CNP, AOCNP
    Nurse Practitioner
    Division of Hematology
    Mayo Clinic
    Rochester, Minnesota

    No financial interests or affiliations to disclose.

    Jeff Sharman, MD
    Willamette Valley Cancer Institute and Research Center
    Medical Director of Hematology Research
    US Oncology
    Eugene, Oregon

    Advisory Committee, Consulting Agreements and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

    RTP CNE (NCPD) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Audio Program Release date: August 2020
    Audio Program Expiration date: August 2021
    Video Program Release date: July 2020
    Video Program Expiration date: July 2021

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Listen to audio:
Select publications